%0 Journal Article
%A Schmid, Sabine
%A Jiang, Mei
%A Brown, M Catherine
%A Fares, Aline
%A Garcia, Miguel
%A Soriano, Joelle
%A Dong, Mei
%A Thomas, Sera
%A Kohno, Takashi
%A Leal, Leticia Ferro
%A Diao, Nancy
%A Xie, Juntao
%A Wang, Zhichao
%A Zaridze, David
%A Holcatova, Ivana
%A Lissowska, Jolanta
%A Świątkowska, Beata
%A Mates, Dana
%A Savic, Milan
%A Wenzlaff, Angela S
%A Harris, Curtis C
%A Caporaso, Neil E
%A Ma, Hongxia
%A Fernandez-Tardon, Guillermo
%A Barnett, Matthew J
%A Goodman, Gary
%A Davies, Michael P A
%A Pérez-Ríos, Mónica
%A Taylor, Fiona
%A Duell, Eric J
%A Schoettker, Ben
%A Brenner, Hermann
%A Andrew, Angeline
%A Cox, Angela
%A Ruano-Ravina, Alberto
%A Field, John K
%A Marchand, Loic Le
%A Wang, Ying
%A Chen, Chu
%A Tardon, Adonina
%A Shete, Sanjay
%A Schabath, Matthew B
%A Shen, Hongbing
%A Landi, Maria Teresa
%A Ryan, Brid M
%A Schwartz, Ann G
%A Qi, Lihong
%A Sakoda, Lori C
%A Brennan, Paul
%A Yang, Ping
%A Zhang, Jie
%A Christiani, David C
%A Reis, Rui Manuel
%A Shiraishi, Kouya
%A Hung, Rayjean J
%A Xu, Wei
%A Liu, Geoffrey
%T Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.
%J Cancer epidemiology, biomarkers & prevention
%V 31
%N 3
%@ 1055-9965
%C Philadelphia, Pa.
%I AACR
%M DKFZ-2022-00486
%P cebp.0747.2021 -
%D 2022
%X Somatic EGFR mutations define a subset of non-small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches.Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status.Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35027437
%R 10.1158/1055-9965.EPI-21-0747
%U https://inrepo02.dkfz.de/record/179129